SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Value Investing
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: cpabobp who wrote (17219)6/12/2003 10:17:27 AM
From: Spekulatius   of 78742
 
RE: VICL or any other "below cash" stocks

While I agree that investing in biotechs below cash may represent a safety net I still think that you need to look at the underlying technology and the chance of success. With biotechs, the cash will be spend sooner or later and if the R&D is wasted on unpromising projects the company will be out of business. As for VICL, I do not like their ?naked DNA technique ; their progress in the clinic is very slow and it is quite questionable if ever anything will be marketable. The only silverlining is a HIV project with Merck which uses their technique as part of the cocktail but i doubt that the small royalties will be sufficient to sustain VICL if this project will be successful.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News